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Abstract  
Recurrent ovarian cancer is considered incurable and the current standard of treatment (surgery and 
chemotherapy) is palliative. For isolated, localized recurrent tumor, brachytherapy with Cesium-131 is a 
promising treatment because of its localized radiation yet limited exposure to healthy tissue. Compared to its 
predecessors, Cs-131 has a very short half-life, allowing for highly localized radiation that decreases toxicity 
of treatment and convenience for the patient. Our case shows a patient diagnosed with recurrent ovarian 
cancer metastatic to the right paraaortic odes. The first successful application of Cs-131 brachytherapy was 
performed with 100% local control without added toxicity. This shows a favorable addition to the current 
standard of care for highly localized ovarian cancers.  
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Introduction 
Ovarian cancer accounts for the most deaths among reproductive cancers in American women [1]. 
Despite high rates of clinical remission following primary therapy, the recurrence rate among ovarian 
carcinoma remains high and recurrent ovarian carcinoma is considered incurable. Thus, treatment for 
recurrent ovarian cancer is palliative, usually consisting of surgery and/or chemotherapy. In cases of 
an isolated, localized recurrent tumor, brachytherapy may be an effective treatment for recurrent 
ovarian cancer because of its localized, high-dose radiation and its ability to limit radiation exposure to 
healthy tissue. Cesium-131 (Cs-131) is an FDA-cleared radioisotope used for brachytherapy which has 
physical and radiobiological advantages over its predecessors (Iodine-125 and Palladium-103). 
Specifically, Cs-131 has a very short half-life of 9.7 days allowing for 90% of the intended dose to be 
delivered in approximately one month. Not only does brachytherapy with Cs-131 allow the immediate 
release of radiation and thus tumor all-kill, which results in prevention of tumor cell repopulation,  
the rapid radiation dose delivery allows for earlier initiation of subsequent systemic chemotherapy. We 
present the first case of successful application of Cs-131 in a patient with recurrent ovarian cancer.   
Case Presentation  
Patient History and Examination:  
The patient is a 66 year old Asian female with a history of grade I, stage 1B endometrioid endometrial 
and stage IC synchronous ovarian cancer who underwent hysterectomy, bilateral 
salpingo-oophorectomy, and lymph node dissection on July 2003 followed by six cycles of adjuvant 
chemotherapy consisting of carboplatin and paclitaxel. The patient was disease-free and asymptomatic 
until December 2010 when she presented with lower back pain that had radiated to her lower abdomen. 
A PET/CT scan on December 2010 demonstrated a new soft tissue mass 2 cm superior to the aortic 
bifurcation which was suspicious for nodal metastasis  (Figure 1A). In addition, there were two new 
soft tissue nodules in the high right common iliac region as well as a ureteral obstruction (Figure 1B). 
A percutaneous biopsy of the suspected lymph nodes was attempted but unsuccessful.  
 
Based on the pre-operative CT scan, the patient underwent a robotic-assisted periaortic lymph node 
dissection and tumor debulking with intraoperative placement of Cs-131 vinyl stranded seed 
brachytherapy. A left ureteral stent was introduced and a right ureterostomy was performed. The 
patient underwent a near complete bilateral periaortic lymph node dissection leaving small residual 
disease in the inferior vena cava and inferior mesenteric artery which was deemed unresectable. A 
frozen section had been obtained from one segment of lymphadenopathy, which returned as consistent 
with malignant cells. Final pathology demonstrated poorly differentiated carcinoma infiltrating 
perinodal fibrous tissue, consistent with recurrent ovarian cancer. All lymph nodes were negative for 
metastatic carcinoma.  
 
The intraoperative Cesium-131 (Cs-131) brachytherapy seeds were applied to the areas of residual 
disease. Cs-131 brachytherapy seeds were stranded on a suture and were threaded through Vicryl mesh. 
Thirty seeds with activity of 2.4 U/seed were implanted amounting to a total dose of 80 Gy prescribed 
to a 5 mm depth (Figure 1C-F). Postoperatively, the patient was given 6 cycles of adjuvant 
chemotherapy with gemcitabine and carboplatin.  
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Figure 1 A PET/CT scan of the abdominal/pelvic region. A. Green markings indicate a new soft tissue 2 cm mass 
superior to the aortic bifurication which is suspicious for neoplastic lymph node. B. Two new soft tissue nodules in 
the high right common iliac region suspicious for periaortic recurrence of ovarian cancer. Computed tomography 
scans of Cs-131 brachytherpay seeds in the postoperative resection cavity. C. Axial plane. D. Coronal plane. E. 
Saggital plane. D: Three-dimensional radiation cloud from the 80-Gy isodose line F. Enlarged axial view of 
isodose lines.  
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CT scans of the abdomen and pelvic region were performed routinely, every 6 months after the resection, to 
assess the residual tumors and recurrence of disease.  A post-operative CT scan showed an edema containing 
para-aortic collection resulting from postsurgical changes and fat necrosis from brachytherapy. 
 
Another PET scan a year after diagnosis showed no residual metabolic activity within the infiltrating para-aortic 
and retroperitoneal mass and complete resolution of edema and fat necrosis. The patient remained asymptomatic 
from the implant. Subsequent PET-CT scans (with the last one obtained in June 2014 – Figure 2) revealed no 
recurrent disease and 100% local control of the implanted area.  
 
 
 
Figure 2 A PET-CT scan obtained 4.5 years later indicates no local recurrence in the area treated with 
brachytherapy.  
Discussion 
Epithelial ovarian carcinomas account for 90% of all ovarian cancers [1]. Endometrioid epithelial 
ovarian cancers account for 16 - 25% of these cases [2]. The current palliative treatment consists of 
surgery (hysterectomy and bilateral salpingo-oophorectomy) [3] and chemotherapy. Despite treatment, 
a recurrence rate of 60-70% has been reported. The current typical palliative treatment for recurrent 
ovarian cancer is combination platinum-based chemotherapy [4].   
 
Radiotherapy is a less common method of treatment, but when it is involved, whole abdomen radiation 
therapy (WART) or pelvic irradiation has been used. Studies have shown that patients with residual 
tumor have higher 5-year improvement rates with abdominopelvic radiotherapy and pelvic 
radiotherapy compared to abdominopelvic radiotherapy and chemotherapy [5]. Complications such as 
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severe bowel toxicity [6] and the increased use of chemotherapy in treating ovarian cancer have 
decreased the use of radiotherapy in treatment. Brachytherapy can reduce these negative side effects of 
external radiation by localizing high radiation doses and limiting radiation to normal tissues, and thus 
potentially sparing a patient severe toxicity. However, such application is best suited for highly 
localized tumor occurrences such as in our patient. In the cases of residual disease of positive margins 
requiring post-operative external-beam radiation, brachytherapy can be a very effective method which 
replaces the commute, length of treatment, and toxicities associated with radiotherapy. Brachytherapy 
seeds can be implanted at time of resection and thus is a convenient and attractive option for patients 
obviating further commute associated with adjuvant external beam radiotherapy. 
 
Recently, Cesium-131 (Cs-131) has been introduced as a promising novel FDA-cleared radioisotope 
with superior radiobiological and physical properties to other radioactive isotopes (such as Iodine-125 
and Palladium-103), having a shorter half-life and strong photon energy (9.7 days and 29 keV) (7). 
This allows much of the total dose to be delivered in a shorter span of time than the two other 
radioisotopes; effectively, 90% of the intended dose is delivered within ~1 month thereby allowing for 
the initiation of systemic therapy [7]. Furthermore, Cs-131 has favorable properties such as good 
dosimetric coverage and limited exposure to staff [8]. A study by Henschke et al also noted beneficial 
absorption characteristics; for example, radiation can be greatly reduced by lead foil, allowing 
shielding of other structures and healthy tissue [9].  
 
Brachytherapy with Cs-131 has yet to be used in ovarian cancer but has been used successfully in 
treating other diseases. A study by Wooten treating gynecologic malignancies with Cs-131 
brachytherapy seeds demonstrated an 84.4% local regional control with no severe side effects reported 
[10]. We report the first application of Cs-131 brachytherapy in a locally recurrent ovarian cancer 
where such treatment conferred 100% local control without added toxicity. 
Conclusion 
This patient is the first of the authors’ knowledge to be successfully treated with Cs-131 brachytherapy 
seeds for recurrent ovarian cancer. We suggest the use of brachytherapy for curative treatment of 
recurrent ovarian cancer in the case of residual disease. More research is underway to standardize 
treatment guidelines and dosimetric coverage for application of Cs-131 to the periaortic region. 
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